Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report details a specific share repurchase transaction executed on April 14, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 550,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,248.50 pence per share; lowest price paid was 1,239 pence per share.
- Treasury Shares Held: 493,224,284 shares (representing 8.72% of total issued share capital and 9.55% of total voting rights).
- Shares in Issue: 5,165,771,119 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's issued share capital through the cancellation of 550,000 repurchased shares. Consequently, the Company's Treasury shareholding increased to 493,224,284 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,165,771,119) for calculating disclosure thresholds under the Financial Services Authority's rules.
- Confirm the updated Treasury share percentage (8.72% of issued capital) for voting rights analysis.
- Note that the repurchased shares were cancelled rather than held indefinitely.